Oral squamous cell carcinoma inhibitor and application thereof

By using rutin inhibitors targeting STAT3, the high recurrence rate and chemotherapy resistance of oral squamous cell carcinoma (OSCC) have been addressed, providing a highly effective and low-toxicity treatment method that significantly inhibits OSCC cell proliferation and migration, promotes apoptosis, and enhances treatment efficacy.

CN121197192APending Publication Date: 2025-12-26ANHUI UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202511470443.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-10-10
Publication Date
2025-12-26

AI Technical Summary

Technical Problem

Current treatments for oral squamous cell carcinoma suffer from high postoperative recurrence rates, strong chemotherapy resistance, and significant systemic toxic side effects. Furthermore, the lack of effective STAT3 inhibitors makes it difficult to improve the five-year survival rate for patients.

Method used

Using rutin as a STAT3 inhibitor, by targeting STAT3 and inhibiting its phosphorylation, the proliferation, migration, and cell membrane invasion of OSCC cells are suppressed, and apoptosis is promoted, providing a novel, highly effective, and low-toxicity treatment strategy.

Benefits of technology

Rutin significantly inhibits the proliferation, migration, and invasion of OSCC cells and promotes apoptosis, providing a novel, highly effective, and low-toxicity treatment strategy that fills a gap in existing technologies.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly discloses an oral squamous cell carcinoma inhibitor and application thereof. The inhibitor takes rutin as an active component. In-vitro experiments prove that rutin can significantly inhibit proliferation, clone formation, migration and invasion ability of OSCC cells in a dose-dependent manner, and effectively induce cell apoptosis. The action mechanism of the rutin is as follows: the rutin can directly target STAT3 protein and inhibit phosphorylation of the STAT3 protein so as to regulate and control a downstream BCL2 / CASP3 apoptosis pathway, thereby playing a role in treating OSCC. Molecular docking results further show that rutin and STAT3 have strong binding capacity. The invention discloses a new application of rutin as an STAT3 inhibitor in treating oral squamous cell carcinoma, and provides a new strategy and a candidate compound for developing high-efficiency and low-toxicity OSCC treatment medicines.
Need to check novelty before this filing date? Find Prior Art